Mechanism of Action
SS-31 concentrates at the inner mitochondrial membrane through electrostatic and hydrophobic interactions, achieving 1000-fold higher concentrations in mitochondria than cytoplasm.
Cardiolipin Stabilization
Cardiolipin is a unique dimeric phospholipid found almost exclusively in the inner mitochondrial membrane, where it is essential for organizing electron transport chain (ETC) complexes into supercomplexes (I-III-IV). SS-31 binds cardiolipin via electrostatic interaction, preventing its peroxidation by reactive oxygen species. Cardiolipin peroxidation dissociates ETC supercomplexes, reducing ATP production efficiency, a key driver of age-related bioenergetic decline.[1]ETC Supercomplex Assembly
By preserving cardiolipin integrity, SS-31 maintains ETC supercomplex (respirasomes) assembly. Respirasome organization improves electron transfer efficiency, reduces electron leak and ROS production, and increases ATP synthesis per unit oxygen consumed (P/O ratio). Aging and disease are associated with progressive respirasome disassembly that SS-31 reverses.[2]Anti-apoptotic Signaling
SS-31 prevents cardiolipin-cytochrome c interaction, the mechanism by which cytochrome c acts as a peroxidase generating mitochondrial ROS. By limiting this pathway, SS-31 reduces mitochondria-driven apoptosis signaling in ischemic and stressed cells.[3]Research Overview
Heart Failure with Preserved Ejection Fraction (HFpEF)
Phase III ClinicalSS-31 (Elamipretide, Bendavia) entered Phase III clinical trials for HFpEF, a form of heart failure with limited treatment options where mitochondrial dysfunction is central to pathology. Phase II EVOLUTION-HF showed improvements in 6-minute walk distance and quality of life measures. HFpEF is the lead clinical indication.[2]
Ischemia-Reperfusion Injury
Strong EvidenceSS-31 reduces infarct size in cardiac ischemia-reperfusion models by 50-60%. Mechanism involves preventing the burst of mitochondrial ROS upon reperfusion (the "reperfusion injury"). Phase I/II trials in acute MI showed positive safety signals and biomarker improvements.[3]
Barth Syndrome and Mitochondrial Myopathy
Phase II ClinicalBarth syndrome (TAFAZZIN mutation causing cardiolipin deficiency) is a direct genetic model of SS-31 mechanism. Phase II TAZPOWER trial showed improved exercise tolerance and quality of life in Barth syndrome patients, providing proof-of-concept for cardiolipin stabilization as a therapeutic mechanism.[2]
Calculate your SS-31 dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Mitochondrial support / longevity | 1–2 mg | Once daily | Subcutaneous |
| Cardiovascular / recovery stack | 2–5 mg | Once daily | Subcutaneous |
| Stacked with MOTS-c + NAD+ | 1 mg SS-31 + 5-10 mg MOTS-c | Once daily | Subcutaneous (separate sites) |
| Conservative start | 1 mg | Once daily | Subcutaneous |
Morning dosing common. No meal timing requirement. SS-31 achieves rapid mitochondrial accumulation within minutes of injection. Synergizes with MOTS-c (AMPK/metabolic axis) and NAD+ (sirtuin" class="wiki-gloss-link">sirtuin/ETC axis) for comprehensive mitochondrial support. The combination of SS-31 + MOTS-c + NAD+ is an established longevity mitochondrial stack.
Research protocols only. Not medical advice.
Peptide Interactions
Safety Profile
SS-31 has been evaluated in multiple Phase II/III clinical trials with an excellent safety record.
Phase III safety data: No dose-limiting toxicities in cardiac Phase III trials. Well tolerated at IV doses up to 0.1 mg/kg/h infusion rates.
Injection site reactions: Mild transient reactions are the most common adverse effect with subcutaneous administration. No systemic adverse effects observed at research doses.
No off-target effects: SS-31's selectivity for mitochondrial membranes minimizes systemic receptor-mediated side effects characteristic of many biological molecules.
No FDA approval: Investigational drug in Phase III trials. Not approved for any therapeutic use. Research peptide use only outside of clinical trials.
References
- [1]Siegel MP, et al. "Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice." Aging Cell. 2013;12(5):763-771.
- [2]Szeto HH. "First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics." Br J Pharmacol. 2014;171(8):2029-2050.
- [3]Cho J, et al. "Mitochondria-targeted antioxidants and metabolic modulators as pharmacological interventions to slow ageing." Biotechnol Adv. 2010;28(4):544-552.